• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages.MST4 激酶通过磷酸化 STAT1 介导的巨噬细胞 M1 极化调节免疫性血小板减少症。
Cell Mol Immunol. 2023 Dec;20(12):1413-1427. doi: 10.1038/s41423-023-01089-8. Epub 2023 Oct 13.
2
High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia.大剂量地塞米松或全反式维 A 酸可使免疫性血小板减少症中巨噬细胞向 M2 型极化的失衡恢复平衡。
J Thromb Haemost. 2017 Sep;15(9):1845-1858. doi: 10.1111/jth.13767. Epub 2017 Aug 5.
3
ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia.ADAP 对 STAT1 信号的抑制调节免疫性血小板减少症中巨噬细胞的吞噬作用。
Cell Mol Immunol. 2022 Aug;19(8):898-912. doi: 10.1038/s41423-022-00881-2. Epub 2022 May 30.
4
Quercetin, a key active ingredient of Jianpi Zishen Xiehuo Formula, suppresses M1 macrophage polarization and platelet phagocytosis by inhibiting STAT3 activation based on network pharmacology.健脾滋肾泻火方的关键活性成分槲皮素基于网络药理学通过抑制信号转导和转录激活因子3(STAT3)的激活来抑制M1巨噬细胞极化和血小板吞噬作用。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):4219-4233. doi: 10.1007/s00210-023-02870-2. Epub 2023 Dec 6.
5
Low-dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter.低剂量地西他滨通过增强 KLF4 与 PPARγ 启动子的结合促进原发性免疫性血小板减少症患者 M2 巨噬细胞极化。
Clin Transl Med. 2023 Jul;13(7):e1344. doi: 10.1002/ctm2.1344.
6
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.依洛尤单抗调节免疫性血小板减少症中单核细胞/巨噬细胞的表型演变和潜在免疫调节作用。
Platelets. 2023 Dec;34(1):2135694. doi: 10.1080/09537104.2022.2135694. Epub 2022 Oct 25.
7
Antigen B from Echinococcus granulosus regulates macrophage phagocytosis by controlling TLR4 endocytosis in immune thrombocytopenia.细粒棘球绦虫的抗原B通过控制免疫性血小板减少症中Toll样受体4(TLR4)的内吞作用来调节巨噬细胞吞噬作用。
Chem Biol Interact. 2025 Jan 25;406:111350. doi: 10.1016/j.cbi.2024.111350. Epub 2024 Dec 12.
8
RBM4 regulates M1 macrophages polarization through targeting STAT1-mediated glycolysis.RBM4 通过靶向 STAT1 介导的糖酵解调节 M1 巨噬细胞极化。
Int Immunopharmacol. 2020 Jun;83:106432. doi: 10.1016/j.intimp.2020.106432. Epub 2020 Apr 2.
9
Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG).应用源于不同性别特异性血浆的 IVIG 治疗 ITP 小鼠的研究。
Int J Mol Sci. 2023 Nov 6;24(21):15993. doi: 10.3390/ijms242115993.
10
Tumor Necrosis Factor-α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia.肿瘤坏死因子-α 阻断纠正原发性免疫性血小板减少症中单核细胞/巨噬细胞失衡。
Thromb Haemost. 2021 Jun;121(6):767-781. doi: 10.1055/s-0040-1722186. Epub 2021 Jan 14.

引用本文的文献

1
Comprehensive review of macrophage models: primary cells and immortalized lines across species.巨噬细胞模型的全面综述:跨物种的原代细胞和永生化细胞系
Front Immunol. 2025 Aug 20;16:1640935. doi: 10.3389/fimmu.2025.1640935. eCollection 2025.
2
Zuoqing granules attenuate ulcerative colitis via macrophage polarization modulation: involvement of the PPAR-γ/NF-κB/STAT1 signaling axis.左清颗粒通过调节巨噬细胞极化减轻溃疡性结肠炎:PPAR-γ/NF-κB/STAT1信号轴的参与
Front Pharmacol. 2025 Aug 11;16:1646545. doi: 10.3389/fphar.2025.1646545. eCollection 2025.
3
N-methyladenosine attenuates tumor-associated macrophages M2 polarization via suppressing the translation of Snail.N-甲基腺苷通过抑制Snail的翻译来减弱肿瘤相关巨噬细胞的M2极化。
Sci China Life Sci. 2025 Aug 21. doi: 10.1007/s11427-024-2897-y.
4
Cell death signaling and immune regulation: new perspectives on targeted therapy for sepsis.细胞死亡信号传导与免疫调节:脓毒症靶向治疗的新视角
Cell Mol Biol Lett. 2025 Aug 15;30(1):99. doi: 10.1186/s11658-025-00784-w.
5
CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.CDKN1A作为艾曲泊帕治疗免疫性血小板减少症的潜在靶点及其对免疫性血小板减少症中巨噬细胞与过渡性B细胞之间通讯的调节作用。
Ann Hematol. 2025 Jun 14. doi: 10.1007/s00277-025-06436-5.
6
Macrophage hitchhiking nanomedicine for enhanced β-elemene delivery and tumor therapy.用于增强β-榄香烯递送和肿瘤治疗的巨噬细胞搭载纳米药物
Sci Adv. 2025 May 23;11(21):eadw7191. doi: 10.1126/sciadv.adw7191. Epub 2025 May 21.
7
YC-4-3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia.新型糖原合酶激酶3β抑制剂YC-4-3减轻原发性免疫性血小板减少症中巨噬细胞的内质网应激
Adv Sci (Weinh). 2025 May;12(17):e2412515. doi: 10.1002/advs.202412515. Epub 2025 Mar 7.
8
The CCL5/CCR5/SHP2 axis sustains Stat1 phosphorylation and activates NF-κB signaling promoting M1 macrophage polarization and exacerbating chronic prostatic inflammation.CCL5/CCR5/SHP2轴维持Stat1磷酸化并激活NF-κB信号通路,促进M1巨噬细胞极化并加剧慢性前列腺炎症。
Cell Commun Signal. 2024 Dec 5;22(1):584. doi: 10.1186/s12964-024-01943-w.
9
β-Hydroxybutyrate suppresses M1 macrophage polarization through β-hydroxybutyrylation of the STAT1 protein.β-羟基丁酸通过对信号转导和转录激活因子1(STAT1)蛋白进行β-羟基丁酰化来抑制M1巨噬细胞极化。
Cell Death Dis. 2024 Dec 3;15(12):874. doi: 10.1038/s41419-024-07268-3.
10
Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC.靶向STK26和ATG4B:miR-22-3p作为肝癌自噬和肿瘤进展的调节因子
Transl Oncol. 2025 Jan;51:102214. doi: 10.1016/j.tranon.2024.102214. Epub 2024 Nov 27.

本文引用的文献

1
Decreased cyclooxygenase-2 associated with impaired megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia.原发性免疫性血小板减少症中环氧合酶-2 减少与巨核细胞生成和血小板生成受损有关。
J Transl Med. 2023 Aug 12;21(1):540. doi: 10.1186/s12967-023-04389-9.
2
Low-dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter.低剂量地西他滨通过增强 KLF4 与 PPARγ 启动子的结合促进原发性免疫性血小板减少症患者 M2 巨噬细胞极化。
Clin Transl Med. 2023 Jul;13(7):e1344. doi: 10.1002/ctm2.1344.
3
Macrophages in immunoregulation and therapeutics.巨噬细胞在免疫调节和治疗中的作用。
Signal Transduct Target Ther. 2023 May 22;8(1):207. doi: 10.1038/s41392-023-01452-1.
4
A bibliometric analysis of primary immune thrombocytopenia from 2011 to 2021.2011 年至 2021 年原发性免疫性血小板减少症的文献计量学分析。
Br J Haematol. 2023 Jun;201(5):954-970. doi: 10.1111/bjh.18692. Epub 2023 Feb 20.
5
Enhancing regulatory T-cell function via inhibition of high mobility group box 1 protein signaling in immune thrombocytopenia.通过抑制高迁移率族蛋白 1 信号通路增强免疫性血小板减少症调节性 T 细胞的功能。
Haematologica. 2023 Mar 1;108(3):843-858. doi: 10.3324/haematol.2022.281557.
6
Impaired mitochondria of Tregs decreases OXPHOS-derived ATP in primary immune thrombocytopenia with positive plasma pathogens detected by metagenomic sequencing.通过宏基因组测序检测到血浆病原体呈阳性的原发性免疫性血小板减少症中,调节性T细胞的线粒体功能受损会降低氧化磷酸化产生的三磷酸腺苷。
Exp Hematol Oncol. 2022 Sep 1;11(1):48. doi: 10.1186/s40164-022-00304-y.
7
Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia.低剂量地西他滨通过 LKB1 调节免疫性血小板减少症中的髓系来源抑制细胞功能。
Blood. 2022 Dec 29;140(26):2818-2834. doi: 10.1182/blood.2022016029.
8
Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia.糖皮质激素受体通过免疫性血小板减少症中的线粒体代谢调节髓系来源的抑制性细胞功能。
Cell Mol Immunol. 2022 Jul;19(7):764-776. doi: 10.1038/s41423-022-00859-0. Epub 2022 Apr 12.
9
Immune thrombocytopenia.免疫性血小板减少症。
Expert Rev Hematol. 2021 Nov;14(11):1013-1025. doi: 10.1080/17474086.2021.1995347. Epub 2021 Nov 18.
10
Immune Thrombocytopenia Treatment.免疫性血小板减少症的治疗
N Engl J Med. 2021 Sep 2;385(10):948-950. doi: 10.1056/NEJMe2110953.

MST4 激酶通过磷酸化 STAT1 介导的巨噬细胞 M1 极化调节免疫性血小板减少症。

MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages.

机构信息

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, 201508, China.

出版信息

Cell Mol Immunol. 2023 Dec;20(12):1413-1427. doi: 10.1038/s41423-023-01089-8. Epub 2023 Oct 13.

DOI:10.1038/s41423-023-01089-8
PMID:37833401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10687271/
Abstract

Primary immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disorder in which macrophages play a critical role. Mammalian sterile-20-like kinase 4 (MST4), a member of the germinal-center kinase STE20 family, has been demonstrated to be a regulator of inflammation. Whether MST4 participates in the macrophage-dependent inflammation of ITP remains elusive. The expression and function of MST4 in macrophages of ITP patients and THP-1 cells, and of a macrophage-specific Mst4 (Mst4) ITP mouse model were determined. Macrophage phagocytic assays, RNA sequencing (RNA-seq) analysis, immunofluorescence analysis, coimmunoprecipitation (co-IP), mass spectrometry (MS), bioinformatics analysis, and phosphoproteomics analysis were performed to reveal the underlying mechanisms. The expression levels of the MST4 gene were elevated in the expanded M1-like macrophages of ITP patients, and this elevated expression of MST4 was restored to basal levels in patients with remission after high-dose dexamethasone treatment. The expression of the MST4 gene was significantly elevated in THP-1-derived M1 macrophages. Silencing of MST4 decreased the expression of M1 macrophage markers and cytokines, and impaired phagocytosis, which could be increased by overexpression of MST4. In a passive ITP mouse model, macrophage-specific depletion of Mst4 reduced the numbers of M1 macrophages in the spleen and peritoneal lavage fluid, attenuated the expression of M1 cytokines, and promoted the predominance of FcγRIIb in splenic macrophages, which resulted in amelioration of thrombocytopenia. Downregulation of MST4 directly inhibited STAT1 phosphorylation, which is essential for M1 polarization of macrophages. Our study elucidates a critical role for MST4 kinase in the pathology of ITP and identifies MST4 kinase as a potential therapeutic target for refractory ITP.

摘要

原发性免疫性血小板减少症(ITP)是一种自身免疫性出血性疾病,其中巨噬细胞起着关键作用。哺乳动物无 sterile-20 样激酶 4(MST4)是生发中心激酶 STE20 家族的成员,已被证明是炎症的调节剂。MST4 是否参与 ITP 中依赖巨噬细胞的炎症仍不清楚。本研究旨在确定 MST4 在 ITP 患者和 THP-1 细胞的巨噬细胞中的表达和功能,以及巨噬细胞特异性 Mst4(Mst4)ITP 小鼠模型中的表达和功能。进行了巨噬细胞吞噬试验、RNA 测序(RNA-seq)分析、免疫荧光分析、免疫共沉淀(co-IP)、质谱(MS)、生物信息学分析和磷酸蛋白质组学分析,以揭示潜在的机制。在 ITP 患者中,MST4 基因的表达水平在扩增的 M1 样巨噬细胞中升高,而在大剂量地塞米松治疗后缓解的患者中,MST4 的这种高表达恢复到基础水平。MST4 基因在 THP-1 衍生的 M1 巨噬细胞中的表达显著升高。沉默 MST4 降低了 M1 巨噬细胞标志物和细胞因子的表达,并损害了吞噬作用,而过表达 MST4 则可增强吞噬作用。在被动性 ITP 小鼠模型中,巨噬细胞特异性敲除 Mst4 减少了脾脏和腹腔灌洗液中的 M1 巨噬细胞数量,减弱了 M1 细胞因子的表达,并促进了 FcγRIIb 在脾脏巨噬细胞中的优势表达,从而改善了血小板减少症。MST4 激酶的下调直接抑制了 STAT1 磷酸化,这对巨噬细胞的 M1 极化至关重要。本研究阐明了 MST4 激酶在 ITP 发病机制中的关键作用,并确定 MST4 激酶是难治性 ITP 的潜在治疗靶点。